BHVN
Price
$13.79
Change
-$0.26 (-1.85%)
Updated
Jul 21, 04:59 PM (EDT)
Capitalization
1.43B
14 days until earnings call
SYRE
Price
$16.35
Change
+$0.06 (+0.37%)
Updated
Jul 21, 04:59 PM (EDT)
Capitalization
986.78M
10 days until earnings call
Interact to see
Advertisement

BHVN vs SYRE

Header iconBHVN vs SYRE Comparison
Open Charts BHVN vs SYREBanner chart's image
Biohaven
Price$13.79
Change-$0.26 (-1.85%)
Volume$14.36K
Capitalization1.43B
Spyre Therapeutics
Price$16.35
Change+$0.06 (+0.37%)
Volume$7.49K
Capitalization986.78M
BHVN vs SYRE Comparison Chart in %
Loading...
BHVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BHVN vs. SYRE commentary
Jul 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BHVN is a Hold and SYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 22, 2025
Stock price -- (BHVN: $14.05 vs. SYRE: $16.29)
Brand notoriety: BHVN and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BHVN: 90% vs. SYRE: 60%
Market capitalization -- BHVN: $1.43B vs. SYRE: $986.78M
BHVN [@Biotechnology] is valued at $1.43B. SYRE’s [@Biotechnology] market capitalization is $986.78M. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BHVN’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • BHVN’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, both BHVN and SYRE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BHVN’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 6 bullish TA indicator(s).

  • BHVN’s TA Score: 4 bullish, 3 bearish.
  • SYRE’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than BHVN.

Price Growth

BHVN (@Biotechnology) experienced а +0.86% price change this week, while SYRE (@Biotechnology) price change was +3.82% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.19%. For the same industry, the average monthly price growth was +15.52%, and the average quarterly price growth was +33.92%.

Reported Earning Dates

BHVN is expected to report earnings on Nov 18, 2025.

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BHVN($1.44B) has a higher market cap than SYRE($987M). SYRE YTD gains are higher at: -30.026 vs. BHVN (-62.383). SYRE has higher annual earnings (EBITDA): -214.36M vs. BHVN (-914.78M). SYRE has more cash in the bank: 565M vs. BHVN (323M). SYRE has less debt than BHVN: SYRE (0) vs BHVN (35.5M). BHVN (0) and SYRE (0) have equivalent revenues.
BHVNSYREBHVN / SYRE
Capitalization1.44B987M145%
EBITDA-914.78M-214.36M427%
Gain YTD-62.383-30.026208%
P/E RatioN/A1.72-
Revenue00-
Total Cash323M565M57%
Total Debt35.5M0-
FUNDAMENTALS RATINGS
BHVN vs SYRE: Fundamental Ratings
BHVN
SYRE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
51
Fair valued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
9257
P/E GROWTH RATING
1..100
10082
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BHVN's Valuation (51) in the Pharmaceuticals Major industry is in the same range as SYRE (74). This means that BHVN’s stock grew similarly to SYRE’s over the last 12 months.

BHVN's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as SYRE (100). This means that BHVN’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as BHVN (100). This means that SYRE’s stock grew similarly to BHVN’s over the last 12 months.

SYRE's Price Growth Rating (57) in the Pharmaceuticals Major industry is somewhat better than the same rating for BHVN (92). This means that SYRE’s stock grew somewhat faster than BHVN’s over the last 12 months.

SYRE's P/E Growth Rating (82) in the Pharmaceuticals Major industry is in the same range as BHVN (100). This means that SYRE’s stock grew similarly to BHVN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BHVNSYRE
RSI
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 6 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
85%
Momentum
ODDS (%)
Bearish Trend 4 days ago
69%
Bullish Trend 4 days ago
84%
MACD
ODDS (%)
N/A
Bullish Trend 4 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 4 days ago
89%
Advances
ODDS (%)
Bullish Trend 5 days ago
74%
Bullish Trend 5 days ago
85%
Declines
ODDS (%)
Bearish Trend 15 days ago
75%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
79%
Bullish Trend 4 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
BHVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DILYX15.210.07
+0.46%
Davis International Y
ACIIX8.820.01
+0.11%
American Century Equity Income I
RTSCX31.59-0.15
-0.47%
Russell Inv Tax-Managed US Mid&Sm Cap C
BPSIX26.63-0.13
-0.49%
Boston Partners Small Cap Value II I
RYHCX83.40-0.86
-1.02%
Rydex Health Care C

BHVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, BHVN has been loosely correlated with SYRE. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if BHVN jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BHVN
1D Price
Change %
BHVN100%
-7.02%
SYRE - BHVN
52%
Loosely correlated
-3.55%
CGON - BHVN
52%
Loosely correlated
-6.01%
BEAM - BHVN
52%
Loosely correlated
+1.47%
IDYA - BHVN
49%
Loosely correlated
-2.26%
RVMD - BHVN
49%
Loosely correlated
-1.92%
More